UNSPSC 51384512: Losmiprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRY6X9550R, chemically known as propionic acid, 2-(3-(p-chlorobenzoyl)-o-tolyloxy)- but generally known as losmiprofen, which bears US NIH Compound Identifier 68922. European Medicines Agency schedules Losmiprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08596MIG.

UNSPSC 51384512 Losmiprofen is a Commodity code that represents pharmaceutical products, though the recent solicitations indexed under it show little direct activity specific to losmiprofen itself. Instead, state and local procurement activity tagged with this code centers on broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. The issuing bodies span state health and human services departments, county community health programs, and multistate cooperative purchasing alliances. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear in the recent posted opportunities. The work being solicited involves supply agreements for naloxone and drug deactivation systems, manufacturer contracts for generic pharmaceuticals and OTC products through authorized wholesalers, and capability assessments for direct pharmacy benefit management models outside traditional PBM arrangements.

The geographic spread reflects activity in Florida, Texas, and Minnesota, with MMCAP's multistate cooperative structure extending participation to Oregon and other member jurisdictions. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI (HHS0017013) issued April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products across participating states, with a proposal deadline of March 26, 2026. The MMCAP procurement specifies cGMP and Drug Supply Chain Security Act compliance, requires distribution through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and weights price competitiveness at 75 percent of evaluation. The Texas RFI targets preliminary market intelligence to inform future formal procurement strategy rather than award a contract immediately. All three solicitations require vendor compliance with federal and state regulatory requirements, including FDA registration and E-Verify employment verification where applicable.